Abstract: Objective:To observe the clinical efficacy of dezocine combined with remifentanil in the sedation and analgesia of Alzheimer's disease patients treated with phacoemulsification.Methods:Sixty Alzheimer's disease patients with grade ASA Ⅰ to Ⅱ treated with phacoemulsification were randomly divided into the dezocine group(30 cases, group D) and control group(30 cases, group R).The group D were treated with 0.25μg·kg^-1·min^-1 of remifentanil for 2 min by vein, then the dosage of remifentanil was adjusted for 0.08μg·kg^-1·min^-1, and the patients were additionally injected using 0.04 mg/kg of dezocine combined with 0.02 to 0.06 mg/kg of midazolam by vein.The group R were treated with 0.25μg·kg^-1·min^-1 of remifentanil for 2 min by wein, then the dosage of remifentanil was adjusted for 0.08μg·kg^-1·min^-1, and the patients were additionally injected using 0.02 to 0.06 mg/kg of midazolam by vein.The midazolam dosage and intraoperative remifentanil dosage were adjusted to maintain the modified observer assessment of sedation ≤2, which was stopped until the end of operation.The mean arterial pressure, heart rate, respiratory rate, oxyhemoglobin saturation, time of operation duration and patients awakening, dosage of remifentanil and midazolam and intraoperative adverse reaction were recorded before anaesthesia, after anesthesia, at the start of operation and at the end of operation.Results:Compared with the group R, the changes of oxyhemoglobin saturation and respiratory frequency in group D were less after anesthesia(P <0.05 to P<0.01), the time of operation duration and patients awakening in group D were shorter(P<0.01), the dosage of remifentanil and midazolam in group D were less(P<0.01), and the incidence of respiratory depression was lower(P<0.05).Conclusions:The clinical effect of dezocine combined with remifentanil in the sedation and analgesia of Alzheimer's disease patients treated with phacoemulsification is good, which is a safe method of anesthesia.